The Role of Contrast Enhanced Endoscopic Ultrasound for Evaluation of Pancreas Lesions

Trial ID: NCT04324294

Interventional - Phase 1 - Unknown status

The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.

Conditions

• Pancreatitis
• Pancreas Cancer
• Pancreas Cyst

Interventions

• EUS enhanced with contrast to evaluate pancreas

Eligibility

Inclusion criteria

• Patients undergoing endoscopic ultrasound for pancreatic indications
• Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings

Exclusion criteria

• Patients \<18 years of age, pregnant women, and lactating mothers will be excluded.
• Subjects with unstable cardiopulmonary condition will be excluded (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias)
• Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts will be excluded given theoretical (though clinically insignificant) risk of embolization
• Patients with a history of allergy to Lumason will be excluded

Sponsor

Cedars-Sinai Medical Center

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows